Feb 27, 2023 / 10:00PM GMT
Kyahn Williamson - Telix Pharmaceuticals Limited - SVP of Corporate Communications & IR
Good morning, good afternoon to those overseas and welcome to the 2022 full year results presentation from Telix Pharmaceuticals. Today, I have on the line Dr. Christian Behrenbruch, our Group CEO and Managing Director; Darren Smith, Group CFO; and Colin Hayward, Chief Medical Officer. My name is Kyahn Williamson. I'm SVP of Investor Relations and Corporate Communications. If we just move to the opening slide, please. You'll notice that we've placed the practice and lodge our full year results, annual report appendix your investor presentation at the close of market yesterday. In Australia, this is really reflecting our increasing global investor base and allowing people some sufficient time to review those documents.
So thank you for tuning in. Just by way of introduction, 2022 has been a really outstanding year for Telix. Notably, we've had a successful launch of Illuccix and the completion of the ZIRCON Phase III study. And I think what this slide shows you here is the achievement of the year really show
Full Year 2022 Telix Pharmaceuticals Ltd Earnings Call Transcript
Feb 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers